STADA, laboratorio líder en medicamentos genéricos y productos para el autocuidado de la salud, presenta el nuevo medicamento Memantina Flas STADAGEN EFG en comprimidos bucodispersablies para el tratamiento de pacientes con enfermedad de Alzheimer de moderada a grave.
Memantina es un fármaco antagonista no competitivo de los receptores NMDA que modula los niveles tónicos de glutamato elevados patológicamente que pueden ocasionar disfunción neuronal asociada al Alzheimer.
Memantina Flas STADAGEN EFG se comercializa en dos presentaciones, de 10 mg 112 comprimidos bucodispersbles y 20 mg 56 comprimidos bucodispersables. Su nuevo formato de comprimidos bucodispersables facilita la toma de la medicación, especialmente en pacientes con dificultades de deglución derivadas de la evolución de la propia enfermedad.
De este modo, STADA refuerza su compromiso con el Alzheimer, una enfermedad que en España afecta a 800.000 personas, aportando no sólo un completo vademécum para el tratamiento de la enfermedad que incluye los fármacos de primera elección como rivastigmina, donepezilo, galantamina y memantina, sino también iniciativas de apoyo a los cuidadores y los profesionales sanitarios como kNOW Alzheimer (knowalzheimer.com).
11 January 2016
Los consejos de Hospiten Estepona para recuperarse de los excesos navideños
Pasadas ya las celebraciones, llega la hora de los buenos propósitos, entre ellos, recuperarse de los excesos en la mesa durante las Navidades.
El Dr. Antonio Abril Rubio del Servicio de Endocrinología de Hospiten Estepona nos ofrece algunos consejos para afrontar este reto.
- Realizar una dieta sana y equilibrada, evitando alimentos precocinados y frituras. Ingerir abundantes frutas y verduras. Añadir a la dieta cereales, pastas o legumbres y reducir el consumo de grasas, de carnes y pescados. También se aconseja para evitar la ansiedad que se hagan cinco comidas diarias.
- Beber vino con moderación, salvo contraindicación médica, se estima el consumo saludable en una copa al día.
- Ingerir abundante agua, en torno a 1.5L-2 litros diarios.
- Realizar ejercicio físico de forma constante, al menos entre dos o tres veces por semana durante una hora.
- Descansar correctamente, con un horario fijo, tras más de una hora de realizar cualquier ingesta.
Sobre el Grupo HOSPITEN
El Grupo HOSPITEN es una red sanitaria internacional comprometida con la prestación de un servicio de máxima calidad, con experiencia de 45 años, que cuenta con diecinueve centros médico-hospitalarios privados en España, República Dominicana, México y Jamaica, y más de cien centros médicos ambulatorios, propios y asociados bajo la marca propia Clinic Assist, atendiendo anualmente a un millón de pacientes de todo el mundo, contando con una plantilla de más de 3.500 personas.
Salud presenta una nueva actividad formativa online sobre uso racional de medicamentos
La página web de CADIME (www.cadime.es) cuenta a partir de ahora con los BTAtest y los casos clínicos del Boletín Terapéutico Andaluz (BTA), herramientas de formación continuada en uso racional de los medicamentos. El objetivo es fomentar el conocimiento sobre uso racional de los medicamentos de los profesionales sanitarios del Sistema Sanitario Público de Andalucía, para ello cada número del BTA se complementa con los BTAtest y casos clínicos del BTA, que ofrecen una actividad formativa autoevaluable, relacionada con el tema tratado en el boletín correspondiente.
BTAtest
Los BTAtest son unos instrumentos de formación on-line que contienen una relación de preguntas multirespuesta, dirigidos principalmente a médicos y farmacéuticos de atención primaria.
Los casos clínicos del BTA plantean la resolución de un caso, similar a los que se presentan en la práctica de la atención primaria, relacionado con el tema al que se dedique el BTA al que corresponde. Con este nuevo enfoque práctico se pretende facilitar la difusión de la información contenida en cada BTA, redundando en el objetivo de uso racional del medicamento.
Ambas actividades formativas permiten la autoevaluación del aprendizaje y ofrecen al usuario la posibilidad de evaluar la actividad y enviar información de retorno si lo desea.
Comenzamos con los dos primeros números del BTA de este año con actividad formativa sobre asma y actividad formativa sobre anticoagulantes + antiagregantes. A lo largo del año se irá incorporando los restantes materiales, hasta completar la edición.
CADIME
El Centro Andaluz de Documentación e Información de Medicamentos (CADIME) tiene como misión promover el uso adecuado de los medicamentos entre los profesionales de la salud de Andalucía, mediante la recuperación, difusión y elaboración de información sobre medicamentos y terapéutica de forma objetiva, científica independiente y sin ánimo de lucro.
Creado en 1982 como primer centro autonómico, está adscrito a la Escuela Andaluza de Salud Pública (EASP) desde 1994. La web de CADIME cuenta con más de 10.600 suscriptores, y permite consultar y descargar más de 175 artículos del Boletín Terapéutico Andaluz (BTA), más de 100 Fichas de evaluación de nuevos medicamentos, Algoritmos de tratamiento farmacológico, Informes, Noticias y Destacados.
European Pain Federation EFIC® launches new information campaign: "European Year Against Pain"
Today, the European Pain Federation EFIC® launched its “European Year Against Pain (EYAP)” campaign in Brussels. In doing so, EFIC is putting a health problem on centre stage, from which more than half the total population over age 50 suffers. “Joint pain is among the most frequent health complaints of all and a leading reason for disability,” EFIC President Dr Chris Wells noted. “Joint pain will become an even more urgent problem in future given the prevalence of a sedentary lifestyle, ever more widespread obesity, and the increase in life expectancy. Like chronic pain in general, joint pain causes not only individual suffering but also has an enormous social cost in the form of health care expenses, sick days off work, loss of productivity or occupational disability.” Figures from the US show the economic dimension involved: Between 1996 and 2011, expenses for the treatment of joint complaints increased more than in any other category, namely by 192 per cent. Throughout the EU, musculoskeletal problems constitute the most important diagnosis category in terms of health care spending and the indirect costs of decreased productivity.
Despite major efforts, currently available therapies are not yielding the desired effects and in some cases fall short of the patients’ expectations. The EFIC President: “Care must be improved substantially. Joint pain sufferers must receive adequate, reliable treatment more quickly, treatment that not only fights pain but also enables the joints to retain their functionality. We want to show what is needed to achieve this objective and raise awareness about how worthwhile it can be to invest in the treatment of joint pain.”
The intent of the European Year Against Joint Pain is to inform the public about the diverse symptoms of joint pain and the possible treatments. That way, pain sufferers could also “seek appropriate help on time,” as EFIC President Dr Wells emphasised. The website www.efic.org makes available collected facts and patient information on the various forms of joint pain. There is a variety of initiatives, PR efforts, and conferences in the 37 countries in which EFIC is represented with national chapters. In September, EFIC will stage a topical seminar on this subject in Dubrovnik, Croatia.
Joint pain can take many forms: at least 150 known types
Until now, some 150 different forms of joint pain have been identified, with very diverse causes. For instance, they can be traced to bone fractures or to previous joint surgeries. The most frequent causes of chronic joint problems, however, are wear-related osteoarthritis, crystal deposits (gout) and inflammatory processes. Prof Bart Morlion, President elect of EFIC and coordinator for the European Year Against Pain: “Today we do not yet sufficiently understand the various causes and mechanisms relating to the broad range of forms that joint pain can take. Until now, researchers have concentrated primarily on the most frequent forms. A number of important new findings have been made recently but still have to find their way into actual practice. They pertain to common mechanisms of incurrence or manifestations of whole different forms of joint pain. Policymakers are called on to create the necessary basic framework for tailor-made programmes geared to different patient groups.” Whereas changes in bones should be treated with corresponding active ingredients, for example, highly obese individuals could be offered weight-reduction programmes. It is still paramount that researchers find answers to the many unanswered questions regarding diagnosis and treatment. Prof Morlion: “We are counting on the European Year Against Joint Pain to provide fresh impetus to these efforts.”
Osteoarthritis and gout as widespread ailments
Gout is the most frequent of the painful inflammatory joint diseases. It is characterised by episodes of acute pain that can also develop into a chronic inflammatory condition. Between one and four per cent of the population suffers from gout. The most frequent inflammatory joint disease with an autoimmune cause is rheumatoid arthritis. Less than one per cent of the global population suffers from this disease, which customarily affects multiple joints.
Osteoarthritis is the most frequent form of painful joint problems. This complex disease is characterised by excess wear to the joints, where mechanical pain can be coupled with inflammatory and/or neuropathic pain. Osteoarthritis accounts for a substantial 20 per cent of all chronic pain worldwide. Ten to fifteen per cent of the global population is affected by this disease and its prevalence clearly rises with age. Among all 60 to 70-year-olds, osteoarthritis is diagnosed in 40 per cent of women and 25 per cent of men. It is the most frequent disease of the musculoskeletal system in older people and is the cause of disability in this group more often than any other condition. Symptoms such as joint pain or stiffness do not occur in all patients for which the disease can be proven on an x-ray. This is the case in ten to fifteen per cent of the population, however. Knee, hand and hip joints are the joints most frequently involved.
Osteoarthritis is more than just a joint disease
For a long time, osteoarthritic pain was neglected and the mechanisms behind it and possible therapies for it were incorrectly assessed. Prof Morlion: “In the meantime, we know that osteoarthritis is more than a joint disease. There is a complex interplay between it on the one hand and obesity, metabolic syndrome and cardiovascular diseases on the other.” Hormone-like messengers such as adipokines, myokines and cytokines were found to be the common denominator of these diseases. They are secreted into the blood by joint tissue, muscles and fat and promote inflammatory processes and cartilage degeneration. Prof Morlion: “The challenge continues to be to treat osteoarthritis in a joint-preserving manner. Recently a decisive step was taken when the various manifestations of osteoarthritis were described. The Osteoarthritis Research Society International (OARSI) also published guidelines for non-surgical treatment. What is new about these guidelines is that they contain varying recommendations depending on the clinical subcategory, for instance, whether comorbidities exist in the case of knee osteoarthritis.” The key treatments suitable for all patients comprise gymnastics and water gymnastics, weight control, strength workouts, and trainings.
Using drugs on a mechanism basis
The goal for joint pain of the most varied kinds has to be to prevent this pain from becoming chronic. On that all experts agree. The risk of this happening is high, however. With osteoarthritis, for instance, many patients do not seek out medical help until a considerable period of time has elapsed. 66 per cent try to improve the situation with non-prescription food additives and drugs while 41 per cent of the patients experience joint pain at least one year prior to the diagnosis.
The range of available therapies is as broad as the causes and manifestations of joint pain are varied. Application of heat and cold, electrotherapies, exercise strategies, strength workouts or weight loss are among the important non-drug treatment approaches. In terms of drug therapy for joint pain, a new approach is becoming increasingly established – namely a selection of substances geared to the mechanisms of the given manifestation of pain. Conventionally, the therapy for joint pain had been geared to the pain severity as modelled on the WHO pain ladder – with non-opioid analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) used for mild severity, “weak” opioids for moderate pain and “strong” opioids for severe pain.
Prof Morlion: “A new approach has now become increasingly established, namely to select the therapy by the mechanism underlying the given pain and by the target of the given drug.” For joint pain, this means that nociceptive inflammatory pain should be treated as a rule by reducing inflammation with steroids or NSAIDs, non-inflammatory nociceptive pain by opioid and non-opioid analgesics, and neuropathic pain by antidepressants or anticonvulsants, or various types of rheumatic disorders with monoclonal antibodies. Prof Morlion: “That is progress because it means the therapies more closely match the patient’s needs than with the conventional escalation strategies from weaker to stronger drugs.”
Under-treatment widespread
For many joint pain sufferers, exhaustive use is not made of the available drug options for pain therapy. One reason is a concern about undesirable effects – especially in elderly patients. Prof Morlion elaborated: “There have been a number of improvements lately, however. New opioids for example have attained sustainable success when used on slight gastrointestinal or cognitive impairments and the risk of dependency is small.” The local administration of pain killers has also been shown to reduce side-effects. Recently published methods involving antibodies that block nerve growth factors show the potential of biological therapies for osteoarthritis, too. They are aimed at peripheral pain mechanisms and hardly penetrate the central nervous system. Thus, side-effects such as sleepiness or nausea are problems of the past. Prof. Morlion urged the following: “Pain should in any case be treated at an early stage, because we can now also determine the cause of it more quickly.”
European Year Against Pain
“Each year we turn attention on a special form of pain or a special health care problem with our regular EYAP information offensive staged in coordination with the International Association for the Study of Pain (IASP)”, said EFIC President Dr Chris Wells Our intent is to point out the health problem of pain in all its facets and consequences, to support pain patients and to sensitize the broader public. In addition, we consider it essential to make policymakers aware of the challenges that chronic pain poses for the health care system and to set a priority in this area.”
La CE autoriza certolizumab pegol para el tratamiento de la artritis reumatoide grave, activa y progresiva en paciente que no han sido tratados con FAME
La Comisión Europea ha concedido a la compañía biofarmacéutica UCB la autorización de comercialización para Certolizumab pegol en combinación con metotrexato para el tratamiento de pacientes adultos con artritis reumatoide grave, activa y progresiva que no han recibido tratamiento previo con fármacos antirreumáticos modificadores de la enfermedad (denominados FAME). Esta autorización se basa en el dictamen positivo emitido hace unos meses por el Comité de Medicamentos de Uso Humano (CHMP, en sus siglas en inglés) de la Agencia Europea del Medicamento (EMA, en sus siglas en inglés).
Los principales datos en los que se ha basado esta aprobación se refieren al estudio C-EARLY que demuestra que Cimzia® en combinación con metotrexato optimizado logra una remisión clínica y una inhibición de la progresión radiográfica mantenidas en el tiempo y con diferencias estadísticamente significativas en comparación con placebo y metotrexato, a la semana 52 del tratamiento, en pacientes con artritis reumatoide que no habían sido tratados previamente con FAME.
“Este relevante estudio proporciona las pruebas que necesitan los profesionales sanitarios para el tratamiento precoz de pacientes con artritis reumatoide, sin exposición previa a FAME y que presentan factores de mal pronóstico de la enfermedad durante el primer año desde el diagnóstico”, destaca el doctor Paul Emery, catedrático de Reumatología en la Universidad de Leeds (Reino Unido) y coordinador del estudio.
Esta autorización supone una extensión de la indicación de Cimzia® en artritis reumatoide que ya estaba aprobado para su uso en combinación con metotrexato para la artritis reumatoide activa de moderada a grave en pacientes que no habían respondido adecuadamente a FAME sintéticos4. En combinación con metotrexato también está indicado para tratar la artritis psoriásica activa en adultos cuando la respuesta previa a FAME no haya sido adecuada. Y este medicamento también cuenta con la autorización en la Unión Europea para el tratamiento de pacientes adultos con espondiloartritis axial (EpAax) activa grave.
Estas autorizaciones confieren a Cimzia® un perfil muy interesante en el tratamiento de pacientes afectados por artritis reumatoide, una enfermedad que puede llegar a ser muy incapacitante.
Los principales datos en los que se ha basado esta aprobación se refieren al estudio C-EARLY que demuestra que Cimzia® en combinación con metotrexato optimizado logra una remisión clínica y una inhibición de la progresión radiográfica mantenidas en el tiempo y con diferencias estadísticamente significativas en comparación con placebo y metotrexato, a la semana 52 del tratamiento, en pacientes con artritis reumatoide que no habían sido tratados previamente con FAME.
“Este relevante estudio proporciona las pruebas que necesitan los profesionales sanitarios para el tratamiento precoz de pacientes con artritis reumatoide, sin exposición previa a FAME y que presentan factores de mal pronóstico de la enfermedad durante el primer año desde el diagnóstico”, destaca el doctor Paul Emery, catedrático de Reumatología en la Universidad de Leeds (Reino Unido) y coordinador del estudio.
Esta autorización supone una extensión de la indicación de Cimzia® en artritis reumatoide que ya estaba aprobado para su uso en combinación con metotrexato para la artritis reumatoide activa de moderada a grave en pacientes que no habían respondido adecuadamente a FAME sintéticos4. En combinación con metotrexato también está indicado para tratar la artritis psoriásica activa en adultos cuando la respuesta previa a FAME no haya sido adecuada. Y este medicamento también cuenta con la autorización en la Unión Europea para el tratamiento de pacientes adultos con espondiloartritis axial (EpAax) activa grave.
Estas autorizaciones confieren a Cimzia® un perfil muy interesante en el tratamiento de pacientes afectados por artritis reumatoide, una enfermedad que puede llegar a ser muy incapacitante.
Más del 40 % de los hombres y más del 60 % de las mujeres de Arabia Saudí sufren deficiencia de vitamina D a pesar de los altos niveles de sol
A pesar de que el Reino de Arabia Saudita es uno de los países del mundo con mayor cantidad de días de sol, un nuevo estudio transversal (1) ha puesto de manifiesto que la deficiencia de vitamina D está muy extendida. Aunque la tradición en este país insta a cubrir la mayor parte de la piel, lo más probable es que la razón principal de esta deficiencia sea la tendencia actual a pasar la mayor parte de la vida en el interior. De los 10 735 participantes que tomaron parte en el estudio durante la primavera/verano de 2013 (todos ellos mayores de 15 años), el 62,65 % de las mujeres y el 40,6 % de los hombres mostraron un déficit de vitamina D; es decir, unos niveles plasmáticos por debajo de los 28 ng/mL que establece el Ministerio de Sanidad de Arabia Saudí.
Los seres humanos suelen satisfacer sus necesidades de vitamina D mediante la exposición de la piel al sol. Un tiempo de exposición relativamente corto (15-30 minutos) al sol fuerte a menudo es suficiente para cubrir los requerimientos diarios. No obstante, algunos factores como el grado de pigmentación de la piel y la genética pueden dar lugar a diferencias importantes. El déficit de vitamina D tiene consecuencias alarmantes para la salud ósea y aumenta el riesgo de padecer enfermedades autoinmunes. Hasta hace poco no se pensaba que los habitantes de países con abundancia de sol, como Arabia Saudí, pudieran presentar algún riesgo. Sin embargo, varios estudios recientes parecen indicar que una parte importante de la población se ve afectada por un problema de deficiencia (2). El nuevo estudio realizado por Tuffaha, et al. (1) ha intentado por primera vez evaluar el riesgo en la población de Arabia Saudí. Los resultados indicaron que las mujeres y las personas obesas eran más propensas a tener unos niveles insuficientes de vitamina D. Solo un pequeño porcentaje de los participantes tomaba suplementos de vitamina D, la mayoría perteneciente a la élite intelectual.
Mientras que Arabia Saudí define la insuficiencia de vitamina D como unos niveles plasmáticos de 28 ng/mL o inferiores, lo cierto es que existe una considerable falta de consenso a escala mundial acerca de los niveles adecuados. De hecho, un reciente estudio de Alshahrani et al. (3) sugiere que la insuficiencia comienza con unos niveles de 32 ng/mL o inferiores.
Por desgracia, los alimentos procesados que se fabrican en Arabia Saudí no suelen enriquecerse con vitamina D (4). Dada la probabilidad de que en un futuro la población saudí pase más tiempo en casa, sería razonable que las autoridades adviertan del riesgo de deficiencia de vitamina D y recomienden el consumo diario de suplementos a los grupos de riesgo, como las mujeres mayores de 50 años.
08 January 2016
2015’s cosmetic trends revealed: ‘Full abdominoplasty’ the fastest growing surgical procedure, while ‘dermal fillers’ prove to be most popular non-surgical treatment
Cosmetic treatments were big news in 2015, ranging from popular procedures like breast implants and lip plumping à la the Kardashian-Jenner dynasty to more subtle dermal fillers for supermodel Cindy Crawford and tattoo removal for queen of style Victoria Beckham. New data from healthcare search engine WhatClinic.com reveals 2015’s most popular surgical and non-surgical treatments and highlights which cosmetic trends will be big in 2016.
A full abdominoplasty was the fastest growing surgical procedure of 2015, with a 351% increase in enquiries*, despite a hefty price tag of £5,491, on average, in the UK. The procedure involves the removal of excess skin and fat from the middle and lower abdomen in order to tighten the muscle and fascia of the abdominal wall.
Breast implants topped the list for the second year in a row as the most popular procedure of the year, with the largest number of enquiries to cosmetic clinics in the UK at an increase of 183% since 2014. This procedure shows no sign of slowing down as it featured as number seven on the top ten list of fastest growing surgical trends even though it includes a price tag of £3,817, on average.
Those looking to reduce their breast size showed a much bigger increase as enquiries for breast reduction surgery soared ahead to be the fourth fastest growing trend for 2015, seeing a 212% increase in enquiries over the last 12 months, and an average price of £5,160. Breast reconstruction also proved to be growing quickly in-demand, coming in at number two on the list, with an average cost of £4,638.
Enquiries for arm lift surgery have increased by 252% since last year and this procedure is set to be one of the more popular in 2016 as number three on the top trends list. Those looking to get rid of their ‘bingo wings’ will pay an average of £4,290 for this procedure.
Liposuction, the second most popular surgical procedure for 2015, increased in popularity by 167%. Now at an average price of £2,800, the procedure increased in price by a third (up from £2,107) since 2014. Tummy tucks also saw a massive increase in enquiries at 209%, and came in as the third most popular treatment in 2015 while also featuring as number five on the top trend list of biggest increase in enquiries.
Commenting on the data trends, Emily Ross, Director of WhatClinic.com, said: “The cosmetic surgery and medical aesthetic industries continue to thrive and 2015 saw a massive increase in enquiries for procedures in the UK. On the surgical side of the market, abdominoplasty is the stand out treatment of 2015.”
“This is an industry that moves quickly. Demand is high, but in some cases, so is the risk. That’s why it’s so important for patients to have realistic expectations, and to not be swayed by offers or deals.”
The following table shows the surgical procedures that have seen the biggest increase in enquiries from UK patients in 2015:
| Procedure |
Increase in enquiries over past year
|
Average price UK
|
| Full Abdominoplasty |
351%
|
£5,491
|
| Breast Reconstruction |
263%
|
£4,638
|
| Arm Lift |
252%
|
£4,290
|
| Breast Reduction |
212%
|
£5,160
|
| Tummy Tuck |
209%
|
£4,647
|
| Butt Lift |
202%
|
£3,373
|
| Breast Implants |
183%
|
£3,817
|
| Calf Implants |
181%
|
£3,141
|
| Breast Lift |
173%
|
£4,798
|
| Neck Lift |
168%
|
£3,528
|
The following table shows the cosmetic surgery procedures that have seen the highest volume of enquiries from UK patients in 2015:
| Procedure |
Increase in enquiries over past year
|
Average price UK
|
| Breast Implants |
183%
|
£3,817
|
| Liposuction |
167%
|
£2,800
|
| Tummy Tuck |
209%
|
£4,647
|
| Rhinoplasty |
150%
|
£3,608
|
| Fat Transfer |
147%
|
£2,476
|
| Labiaplasty |
134%
|
£2,877
|
| Eyelid surgery |
81%
|
£2,193
|
| Gynecomastia |
120%
|
£3,753
|
| Otoplasty |
101%
|
£2,279
|
| Facelift |
162%
|
£4,921
|
Non-surgical treatments:
Focusing on non-surgical treatment trends, thread lift was the fastest growing treatment with the biggest increase in enquiries at a whopping 470% compared to 2014, when it also topped the trends list. The price tag has increased alongside its interest, from £570 in 2014 to £645 in 2015 (up 13%), on average in the UK.
A newcomer to the list, chin augmentation comes in at number two on the top trends list with a 156% increase in enquiries. The treatment has an average price of £338 and is now the second fastest growing procedure in the UK and looks to become even more popular in 2016.
Enquiries for platelet rich plasma fillers, also known as the ‘Vampire Facial’, increased by 152% over the past 12 months, and are now the third fastest growing non-surgical procedure in the UK with an average price of £416 per session.
Following on from 2014, the top three most popular treatments remain the same for 2015 with dermal fillers at number one with the highest volume of enquiries and saw a further increase in enquiries (up 113%), followed by mole removal (up 114%) and then lip augmentation at number three (up 114%) and all three featured on the top trends list too.
As the most popular procedure two years in a row, dermal fillers experienced a drop in price of 10% compared to 2014, now costing an average price of £252. As eighth on the list for largest increase in enquiries, dermal fillers will continue to be in high-demand for 2016.
Enquiries for tattoo removal have increased by 73% since last year, moving up to fourth place on the popularity list, and those looking to get rid of their etching can expect to pay £63 on average per treatment - with many tattoos requiring three to five sessions for removal.
The following table shows the non-surgical cosmetic treatments that have seen the biggest increase in enquiries from UK patients in 2015:
| Procedure |
Increase in enquiries over past year
|
Average price UK
|
| Thread Lift |
470%
|
£645
|
| Chin Augmentation |
156%
|
£338
|
| Platelet Rich Plasma Filler |
152%
|
£416
|
| Treatment for Wrinkles |
121%
|
£201
|
| Mole Removal |
114%
|
£212
|
| Laser Lipolysis |
114%
|
£779
|
| Lip Augmentation |
114%
|
£284
|
| Dermal Fillers |
113%
|
£252
|
| Carboxytherapy |
105%
|
£96
|
| Scar Removal |
93%
|
£208
|
The following table shows the non-surgical cosmetic treatments that have seen the highest volume of enquiries from UK patients in 2015:
| Procedure |
Increase in enquiries over past year
|
Average price UK
|
| Dermal Fillers |
113%
|
£252
|
| Mole Removal |
114%
|
£212
|
| Lip Augmentation |
114%
|
£284
|
| Tattoo Removal |
73%
|
£63
|
| Spider Veins Treatment |
58%
|
£107
|
| Scar Removal |
93%
|
£208
|
| Non-Surgical Nose Job |
54%
|
£335
|
| Facial Thread Veins Treatment |
89%
|
£107
|
| Thread Lift |
470%
|
£645
|
| Sclerotherapy |
53%
|
£187
|
Ms. Ross continued: “Regarding non-surgical treatments, injectables are more popular than ever, with record demand for dermal fillers in particular. Botox-type wrinkle treatments and lip augmentation have definitely gone mainstream in comparison to just a few short years ago.
“Sometimes it’s better to wait for the ’latest’ thing to become tried and tested before you sign on the dotted line. Nothing is risk free, so start by researching the treatment. Reading reviews is a good way to start!”
Subscribe to:
Comments (Atom)